Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to cquire InflammX Therapeutics during an agreed-upon option period based on ...

Soliddd, an optical and vision technology company, will debut the beta headset version of its virtual reality smart glasses ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

LAS VEGAS and NEW YORK, Jan. 6, 2025 /PRNewswire/ -- SolidddVision™ smartglasses, the first true vision correction for people ...

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy ...